REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT (Q2035362): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Created claim: intervention field (P888): Technology transfer and university-enterprise cooperation primarily benefiting SMEs (Q200702), Adding CoI) |
||
| Property / intervention field | |||
| Property / intervention field: Technology transfer and university-enterprise cooperation primarily benefiting SMEs / rank | |||
Normal rank | |||
Revision as of 13:24, 25 September 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT |
Project in Italy financed by DG Regio |
Statements
423,871.16 Euro
0 references
847,742.32 Euro
0 references
50.0 percent
0 references
13 December 2016
0 references
6 July 2019
0 references
ISTITUTI FISIOTERAPICI OSPITALIERI - IFO
0 references
TAKIS SRL
0 references
ISTITUTO BIOCHIMICO ITALIANO G. LORENZINI
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
REVER3MAB: UN ANTICORPO MONOCLONALE DIRETTO CONTRO LA PROTEINA ERBB3 IN GRADO DI BLOCCARE LA PROLIFERAZIONE DELLE CELLULE TUMORALI IN VITRO E IN VIVO, CON POTENZIALE USO COME AGENTE TERAPEUTICO IN CLINICA. (Italian)
0 references
REVER3BAB: A MONOCLONAL ANTIBODY AGAINST THE ERBB3 PROTEIN CAPABLE OF BLOCKING IN VITRO AND IN VIVO CANCER CELLS, WITH POTENTIAL USE AS A THERAPEUTIC AGENT IN CLINICAL USE. (English)
0 references
Identifiers
F87H18000370007
0 references